dr. azad on the benefit of adding enzalutamide to adt in mhspc
Published 3 years ago • 685 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:47
dr. azad on the post-hoc analysis results of the arches study in mhspc
-
1:24
dr. stenzl on the safety profile of enzalutamide/adt in mhspc
-
1:50
dr. kohli on the use of enzalutamide and apalutamide in mhspc
-
5:11
enzalutamide adt in men with de novo mhspc: the arches trial
-
2:18
arches: enzalutamide plus adt in mhspc subgroups
-
27:00
metabolic side effects of adt
-
7:00
comparing the second generation hormone therapies | ask a prostate expert, mark scholz, md
-
6:21
what is adjuvant hormone therapy for prostate cancer | ask a prostate expert, mark scholz, md
-
2:37
arches trial: enzalutamide plus adt for mhspc
-
2:04
dr. azad on unmet needs in metastatic hormone-sensitive prostate cancer
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
1:37
arches: os in mhspc who recieved prior adt and reached low psa further treated with enzalutamide
-
1:55
arches trial overview: adt plus enzalutamide for metastatic hormone-sensitive prostate cancer
-
6:06
enzalutamide plus androgen deprivation therapy prolongs survival in men with metastatic hormone-...
-
3:38
enzalutamide as treatment for men with mhspc who have received testosterone suppression
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
3:03
arches post-hoc analyses: efficacy of enza adt in mhspc by pattern of metastatic spread
-
1:03
dr. zhang on the arches trial in prostate cancer
-
3:43
arches trial: androgen deprivation therapy with enzalutamide or placebo in mhspc
-
1:14
dr. dreicer on abiraterone and enzalutamide in prostate cancer
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc